# Safety and Efficacy of Pegylated Exenatine Injection (PB-119) in Drug-naïve T2DM Subjects

> **NCT04504370** · PHASE3 · COMPLETED · sponsor: **PegBio Co., Ltd.** · enrollment: 273 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus (T2DM)

## Interventions

- **DRUG:** GLP-1 receptor agonist
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04504370
- **Lead sponsor:** PegBio Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-04-27
- **Primary completion:** 2022-03-30
- **Final completion:** 2022-11-28
- **Target enrollment:** 273 (ACTUAL)
- **Last updated:** 2023-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04504370

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04504370, "Safety and Efficacy of Pegylated Exenatine Injection (PB-119) in Drug-naïve T2DM Subjects". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04504370. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*